850451-50-2

Usage

Physical state

Yellow solid

Molecular weight

230.04 g/mol

Usage

Starting material for organic synthesis (preparation of pharmaceutical and agrochemical products), intermediate in the synthesis of dyes and pigments

Properties

Herbicidal and pesticidal

Toxicity

Toxic and harmful if ingested, inhaled, or if it comes into contact with the skin

Upstream product

• 3215-64-3 2,6-dichlorophenylacetonitrile 

Downstream Products

• 850451-51-3 3-(2,6-dichloro-3-nitro-phenyl)-[1,6]naphthyridin-2-ylamine 
• 34915-66-7 (2,6-dichloro-3-nitro-phenyl)-acetic acid 
• 850450-10-1 N-[2,4-dichloro-3-(1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide 
• 850450-11-2 N-[2,4-dichloro-3-(1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-phenyl]-3-trifluoromethyl-benzenesulfonamide 
• 850451-56-8 4-chloromethyl-N-[2,4-dichloro-3-(1-methyl-2-oxo-1,2-dihydro-[1,6]naphthyridin-3-yl)-phenyl]-benzamide 
• 850451-52-4 3-(2,6-dichloro-3-nitro-phenyl)-1H-[1,6]naphthyridin-2-one 
• 850451-54-6 3-(2,6-dichloro-3-nitro-phenyl)-1-methyl-1H-[1,6]naphthyridin-2-one 
• 850451-60-4 3-(3-amino-2,6-dichloro-phenyl)-1-methyl-1H-quinolin-2-one 
• 850451-55-7 3-(3-amino-2,6-dichloro-phenyl)-1-methyl-1H-[1,6]naphthyridin-2-one 
• 101486-14-0 C₈H₄Cl₃NO₃ 
• 850451-79-5 (3-amino-2,6-dichloro-phenyl)-acetonitrile 

Relevant academic research and scientific papers

Dichlorophenylacrylonitriles as AhR Ligands That Display Selective Breast Cancer Cytotoxicity in vitro

Knoevenagel condensation of 3,4-dichloro- and 2,6-dichlorophenylacetonitriles gave a library of dichlorophenylacrylonitriles. Our leads (Z)-2-(3,4-dichlorophenyl)-3-(1H-pyrrol-2-yl)acrylonitrile (5) and (Z)-2-(3,4-dichlorophenyl)-3-(4-nitrophenyl)acryloni

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF beta , SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2 beta kinases.